Target validation using Phase 0 clinical trials: Promises and pitfalls.
Angelo
Laura S
LS
Department of Investigational Cancer Therapeutics (Phase I Program), The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
Kurzrock
Razelle
R
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic / Q000379:methods*; D015507:Drugs, Investigational / Q000627:therapeutic use*; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*
D000970:Antineoplastic Agents; D015507:Drugs, Investigational